Your donation will make a difference:
Cystic Fibrosis Trust

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial will be added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

1-5 of 28 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Study design

Location

Mutation

Therapeutic category

VX14-661-110 Cystic Fibrosis

This is a Phase 3, OpenLabel, Rollover study to look at how safe and effective longterm treatment with VX-661 together with Ivacaftor is in paticipants aged 12 years and older with cystic fibrosis (CF) that have a F508de-lCFTR mutation. The study involves treating all participants who meet all the rules of the study from one of the parent studies (VX-661-106,108,109 or 111) with a combination of VX-661 and Ivacaftor for approximately 96 weeks with a follow-up 28 days after the last dose. Approximately 1375 participants are potentially eligible to be enrolled. There is also an observational cohort (group) that will enable participants under 18 years of age that received at least 4 weeks of the study drug in the parent study who meet the other rules of the study to enroll. These participants will not receive any study drug but they will have regularly scheduled telephone calls to assess post treatment safety of the combination of VX661/Ivacaftor.

Phase III
  • Length of participation

    96 weeks

  • Trial status

    Open

  • Therapeutic category

    Restore CFTR Function

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy

The single treatment group will enroll adult subjects with CF currently on stable KALYDECO® background therapy for a minimum of 3 months at the time of randomization. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 14 Days. The subjects will continue treatment with KALYDECO® throughout the study.

Phase I
  • Age

    18+

  • Length of participation

    21 weeks

  • Trial status

    Open to recruitment

  • Therapeutic category

    Restore CFTR Function

HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness

Evaluation of potential mucus clearing treatment for all patients with CF regardless of mutation

Phase II
  • Age

    18+

  • Length of participation

    31 days

  • Trial status

    Open to recruitment

  • Therapeutic category

    Mucociliary Clearance

Virtual Care in CF (VIRTUAL-CF)

This study aims to find out if CF patients benefit from ‘virtual care’ while they are receiving intravenous (IV) antibiotics in the community. ‘Virtual care’ is a term that we are using to describe the provision of regular videoconferencing with the CF team as well as equipment to allow patients to monitor their own lung function and oxygen saturations.

Pilot/Feasibility
  • Age

    18+

  • Length of participation

    2 weeks

  • Trial status

    Open

  • Therapeutic category

    Other

MAGIC- a self-management education programme for people with CFRD

Cystic fibrosis (CF) is a life-shortening genetic disease that damages many of the body’s organs, including the lungs, pancreas and digestive system. Cystic fibrosis related diabetes (CFRD) is the most common complication of CF, affecting 45-50% of adults. CFRD is different from type 1 and 2 diabetes and needs specialist dietary and clinical management. CFRD has a significant effect on nutrition, lung function and survival. The need to educate people with CFRD is important because, keeping blood glucose controlled results in improvements in nutrition, and reduces the development of long term complications from CFRD, including death. NICE recommends that everyone with diabetes should be offered a place on a diabetes self-management education (DSME) programme. However, there are currently no DSME programmes specifically for people with CFRD and there is little evidence to base them on. This study, informed by the Medical Research Council’s framework for developing complex interventions, aims to develop an evidence-based self-management education programme for people with CFRD that, will be called MAGIC (Managing Abnormal Glucose In Cystic fibrosis). Stage one is a synthesis of qualitative studies and qualitative patient interviews. This will identify patients’ experiences of living with CFRD and their barriers and facilitators to CFRD self-management. It will help establish what educational input people with CFRD want and identify the skills and knowledge people with CFRD require. Stage one will inform stage two. Stage two is the development of the MAGIC programme by a working group of lay members and healthcare professionals. The MAGIC programme will be evaluated with ten CFRD patients within the hospital. This will help inform future studies required to evaluate its effectiveness (feasibility study), and if appropriate a randomised control trial for evaluating the cost-effectiveness and the impact on well-being and survival of the MAGIC programme at a national level.

Not Applicable
  • Length of participation

    2 days

  • Trial status

    Open to recruitment

  • Therapeutic category

    Nutritional-GI

1-5 of 28 results for all trials